Poly(Adenosine Diphosphate-Ribose) Polymerase Inhibition as Maintenance Treatment for SCLC: The Search Must Continue

J Thorac Oncol. 2021 Aug;16(8):1236-1238. doi: 10.1016/j.jtho.2021.05.016.

Authors

Prerana Huddar¹, Raffaele Califano²

Affiliations

¹ Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
² Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom. Electronic address: raffaele.califano@nhs.net.

PMID: 34304849
DOI: 10.1016/j.jtho.2021.05.016

No abstract available

Publication types

Editorial
Comment

MeSH terms

Adenosine Diphosphate
Humans
Lung Neoplasms* / drug therapy
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
Poly(ADP-ribose) Polymerases
Ribose*

Substances

Poly(ADP-ribose) Polymerase Inhibitors
Adenosine Diphosphate
Ribose
Poly(ADP-ribose) Polymerases